Quantum BioPharma Refutes Law Firm Claims of Securities Violations

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has issued a formal response rejecting what it described as vague and unsubstantiated claims made by The Schall Law Firm and DJS Law Group regarding alleged securities law violations. The company stated that the announcements lack factual detail or context and appear intended to mislead investors and provoke unwarranted concern.

The biopharmaceutical company said it is reviewing the conduct of both firms and their principals and will take appropriate action to address what it believes is a deliberate attempt to harm its reputation. This development is significant for investors and the broader biopharmaceutical sector as it highlights the potential impact of legal announcements on company valuations and investor confidence, particularly for companies in the development stage of innovative treatments.

Quantum BioPharma is dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of its lead compound, Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.

The company also maintains strategic business interests through its ownership stake in Unbuzzd Wellness Inc., where Quantum BioPharma retains 20.11% ownership as of March 31, 2025, along with royalty payments of 7% of sales from unbuzzd(TM) until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

For investors seeking additional information, the company maintains its newsroom at https://ibn.fm/QNTM where updates relating to QNTM are available. The full press release containing the company's response to the law firm announcements can be viewed at https://ibn.fm/TsBbx.

This situation underscores the importance of transparency in corporate communications and the potential consequences of unsubstantiated legal claims on emerging biopharmaceutical companies. For companies like Quantum BioPharma that are developing treatments for serious medical conditions, maintaining investor confidence is crucial for continued research and development funding. The company's portfolio includes strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.